Allaire N, Griesenbach U, Kerem B, Lueck J, Stanleigh N, Oren Y
J Cyst Fibros. 2023; 22 Suppl 1:S39-S44.
PMID: 36658041
PMC: 10012168.
DOI: 10.1016/j.jcf.2022.12.016.
Allan K, Astore M, Fawcett L, Wong S, Chen P, Griffith R
Front Pediatr. 2022; 10:1062766.
PMID: 36467478
PMC: 9709344.
DOI: 10.3389/fped.2022.1062766.
Yeh H, Sutcliffe K, Sheppard D, Hwang T
Handb Exp Pharmacol. 2022; 283:219-247.
PMID: 35972584
DOI: 10.1007/164_2022_597.
Cholon D, Gentzsch M
Curr Opin Pharmacol. 2022; 64:102210.
PMID: 35462105
PMC: 9167699.
DOI: 10.1016/j.coph.2022.102210.
Farinha C, Gentzsch M
Int J Mol Sci. 2021; 22(24).
PMID: 34947992
PMC: 8703571.
DOI: 10.3390/ijms222413196.
Identification of Compounds That Promote Readthrough of Premature Termination Codons in the CFTR.
Smith E, Dukovski D, Shumate J, Scampavia L, Miller J, Spicer T
SLAS Discov. 2020; 26(2):205-215.
PMID: 33016182
PMC: 7838340.
DOI: 10.1177/2472555220962001.
Decreased mRNA and protein stability of W1282X limits response to modulator therapy.
Aksit M, Bowling A, Evans T, Joynt A, Osorio D, Patel S
J Cyst Fibros. 2019; 18(5):606-613.
PMID: 30803905
PMC: 6706327.
DOI: 10.1016/j.jcf.2019.02.009.
In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies.
McGarry M, Illek B, Ly N, Zlock L, Olshansky S, Moreno C
Pediatr Pulmonol. 2017; 52(4):472-479.
PMID: 28068001
PMC: 5461115.
DOI: 10.1002/ppul.23659.
Restoration of R117H CFTR folding and function in human airway cells through combination treatment with VX-809 and VX-770.
Gentzsch M, Ren H, Houck S, Quinney N, Cholon D, Sopha P
Am J Physiol Lung Cell Mol Physiol. 2016; 311(3):L550-9.
PMID: 27402691
PMC: 5142211.
DOI: 10.1152/ajplung.00186.2016.
From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations.
Veit G, Avramescu R, Chiang A, Houck S, Cai Z, Peters K
Mol Biol Cell. 2016; 27(3):424-33.
PMID: 26823392
PMC: 4751594.
DOI: 10.1091/mbc.E14-04-0935.
Cystic fibrosis genetics: from molecular understanding to clinical application.
Cutting G
Nat Rev Genet. 2014; 16(1):45-56.
PMID: 25404111
PMC: 4364438.
DOI: 10.1038/nrg3849.
Assessing the Disease-Liability of Mutations in CFTR.
Ferec C, Cutting G
Cold Spring Harb Perspect Med. 2012; 2(12):a009480.
PMID: 23209179
PMC: 3543074.
DOI: 10.1101/cshperspect.a009480.
Determination of the consequences of VHL mutations on VHL transcripts in renal cell carcinoma.
Taylor C, Craven R, Harnden P, Selby P, Banks R
Int J Oncol. 2012; 41(4):1229-40.
PMID: 22825683
PMC: 3583750.
DOI: 10.3892/ijo.2012.1561.
Pharmacological correction of a defect in PPAR-gamma signaling ameliorates disease severity in Cftr-deficient mice.
Harmon G, Dumlao D, Ng D, Barrett K, Dennis E, Dong H
Nat Med. 2010; 16(3):313-8.
PMID: 20154695
PMC: 2834836.
DOI: 10.1038/nm.2101.
No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations.
Clancy J, Rowe S, Bebok Z, Aitken M, Gibson R, Zeitlin P
Am J Respir Cell Mol Biol. 2007; 37(1):57-66.
PMID: 17347447
PMC: 1899350.
DOI: 10.1165/rcmb.2006-0173OC.
Cystic fibrosis transmembrane regulator protein mutations: 'class' opportunity for novel drug innovation.
MacDonald K, McKenzie K, Zeitlin P
Paediatr Drugs. 2007; 9(1):1-10.
PMID: 17291132
DOI: 10.2165/00148581-200709010-00001.
Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin.
Linde L, Boelz S, Nissim-Rafinia M, Oren Y, Wilschanski M, Yaacov Y
J Clin Invest. 2007; 117(3):683-92.
PMID: 17290305
PMC: 1783999.
DOI: 10.1172/JCI28523.
Targeted therapy for cystic fibrosis: cystic fibrosis transmembrane conductance regulator mutation-specific pharmacologic strategies.
Rubenstein R
Mol Diagn Ther. 2006; 10(5):293-301.
PMID: 17022692
DOI: 10.1007/BF03256204.
Nonsense-mediated decay of human HEXA mRNA.
Rajavel K, Neufeld E
Mol Cell Biol. 2001; 21(16):5512-9.
PMID: 11463833
PMC: 87273.
DOI: 10.1128/MCB.21.16.5512-5519.2001.
In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR.
Rubenstein R, Egan M, Zeitlin P
J Clin Invest. 1997; 100(10):2457-65.
PMID: 9366560
PMC: 508446.
DOI: 10.1172/JCI119788.
